Janet Rae
General Counsel chez APPLIED GENETIC TECHNOLOGIES CORPORATION
Profil
Janet C.
Rae is currently the Senior Vice President-Global Regulatory & Quality at Beacon Therapeutics (USA), Inc. Prior to this, she was the VP & Head-Gene Therapy Regulatory Affairs at Ultragenyx Pharmaceutical, Inc. from 2017 to 2021.
Before that, she was the Vice President & Head-Global Regulatory Affairs at Dimension Therapeutics, Inc. Ms. Rae completed her undergraduate degree at Gordon College (Georgia).
Postes actifs de Janet Rae
| Sociétés | Poste | Début |
|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPORATION | General Counsel | 18/06/2021 |
Anciens postes connus de Janet Rae
| Sociétés | Poste | Fin |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/06/2021 |
| DIMENSION THERAPEUTICS INC | General Counsel | - |
Formation de Janet Rae
| Gordon College (Georgia) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
